PLUS THERAPEUTICS, INC.

# Plus Therapeutics, Inc. (PSTV)

A clinical-stage pharmaceutical company headquartered in Houston, Texas, Plus Therapeutics develops radiotherapeutic and targeted delivery treatments for cancer patients. The company's primary focus is oncology, with its lead candidate REYOBIQ, a patented radiotherapy designed for central nervous system malignancies including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, a therapeutic agent administered via intra-arterial injection to treat primary and secondary liver cancers and other solid organ malignancies.

Beyond drug development, Plus Therapeutics maintains a laboratory-developed testing business. The CNSide Test identifies tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, representing an ancillary revenue stream focused on diagnostic services for cancer patients.

The company operates with a lean organizational structure of 21 full-time employees and maintains a market capitalization of approximately $100 million. The company was incorporated in Delaware and trades on the Nasdaq. Previously known as Cytori Therapeutics, Inc., the organization was founded in 1996 and underwent a rebranding to Plus Therapeutics in July 2019 to reflect its strategic shift toward oncology-focused treatments.